Calidi Biotherapeutics Secures $6 Million in Public Offering
Calidi Biotherapeutics Announces $6 Million Public Offering
Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) has recently made headlines by pricing an underwritten public offering, which is set to yield gross proceeds of $6 million. This is an exciting development for the clinical-stage biotechnology company, known for pioneering targeted therapies aimed at delivering genetic medicines to areas afflicted by disease.
Confidence in Challenging Markets
"We are extremely pleased to have priced this transaction despite difficult market conditions," expressed Eric Poma, Chief Executive Officer of Calidi Biotherapeutics. His words reflect the confidence that the company has fostered among existing shareholders and new investors, along with participation from management and board members, indicative of strong trust in the company's future.
Details of the Offering
The offering consists of several components: 1,472,764 common stock units, where each unit comprises one share of common stock alongside a Series I warrant allowing the purchase of one additional share of common stock. Additionally, there are 1,528,000 pre-funded warrant units, which include a pre-funded warrant to acquire one share of common stock and an accompanying Series I warrant.
The Common Stock Units are priced at $2.00 each, while the Pre-Funded Units are available at $1.999. The Series I warrants have a fixed exercise price of $2.00 per share and will be exercisable upon issuance, remaining valid for five years. This offering is noteworthy because it features fixed-price warrants without any variable pricing components.
Support from Financial Partners
Ladenburg Thalmann & Co. Inc. has taken on the role of sole book-running manager for the offering, while Laidlaw & Company (U.K.) Ltd. serves as a co-manager. Their involvement adds a layer of credibility and expertise, helping to navigate the offering process effectively.
Potential for Expansion
In a strategic move, Calidi Biotherapeutics has granted underwriters a 45-day option to purchase up to an additional 450,000 shares of common stock and/or warrants at the public offering price, minus any underwriting discounts and commissions. This opportunity allows for possible future expansion that could bolster the company’s resources.
Regulatory Compliance and Future Prospects
The offering is planned to close around August 21, 2025, provided all customary closing conditions are met. The associated securities are being issued under a registration statement on Form S-1, which has already received approval from the United States Securities and Exchange Commission (SEC).
Currently, Calidi is pursuing the registration and availability of securities in compliance with SEC regulations. A preliminary prospectus concerning this offering was previously filed and is accessible via the SEC's official website.
About Calidi Biotherapeutics
Calidi Biotherapeutics is forging paths in the realm of immuno-oncology. Their innovative Redtail platform utilizes engineered enveloped oncolytic viruses designed for systemic delivery to metastatic sites, allowing for enhanced virotherapy effectiveness. This technology aims to protect the viral agents from immune system clearance, ensuring they reach tumor sites for optimal results.
The lead candidate from this platform, currently undergoing IND-enabling studies, is targeting non-small cell lung cancer, ovarian cancer, and other malignancies that present high unmet medical needs. Additionally, Calidi is developing protected virotherapies for intratumoral and localized administration, focusing on specific injectable cancer treatment indications.
Headquartered in San Diego, California, Calidi Biotherapeutics stands at the frontier of innovative cancer treatments. To learn more about their groundbreaking work, interested parties can visit www.calidibio.com.
Frequently Asked Questions
What is the purpose of Calidi's recent public offering?
The public offering aims to raise funds to support Calidi's innovative research and development in targeted therapies for cancer treatment.
Who is managing the public offering for Calidi?
Ladenburg Thalmann & Co. Inc. is the sole book-running manager, with Laidlaw & Company (U.K.) Ltd. acting as a co-manager.
What does the Redtail platform focus on?
Calidi's Redtail platform specializes in utilizing engineered viruses to deliver genetic therapies directly to difficult-to-reach tumor sites in the body.
What conditions are targeted by Calidi's leading candidate?
The lead candidate targets various cancers, including non-small cell lung cancer and ovarian cancer, addressing significant medical needs.
Where can investors find more information about Calidi Biotherapeutics?
Investors can obtain more information by visiting Calidi Biotherapeutics' official website or directly contacting their Investor Relations department.
About The Author
Contact Addison Perry privately here. Or send an email with ATTN: Addison Perry as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.